Trial Profile

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NNZ 2591 (Primary)
Indications Angelman syndrome
Focus Adverse reactions; Pharmacokinetics
Acronyms AS-001
Sponsors Neuren Pharmaceuticals

Most Recent Events

07 Aug 2024 Status changed from active, no longer recruiting to completed.
20 Dec 2023 According to a Neuren Pharmaceuticals media release, company announced that the last subject to be screened this week will complete the enrolment of subjects in this trial.
20 Dec 2023 According to a Neuren Pharmaceuticals media release, top-line results from the trial are expected to be available in Q3 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com